These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 23534447)
1. Emerging role of long acting muscarinic antagonists for asthma. Lipworth BJ Br J Clin Pharmacol; 2014 Jan; 77(1):55-62. PubMed ID: 23534447 [TBL] [Abstract][Full Text] [Related]
2. Muscarinic antagonists in early stage clinical development for the treatment of asthma. Albertson TE; Chenoweth JA; Adams JY; Sutter ME Expert Opin Investig Drugs; 2017 Jan; 26(1):35-49. PubMed ID: 27927039 [TBL] [Abstract][Full Text] [Related]
3. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Kew KM; Dahri K Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035 [TBL] [Abstract][Full Text] [Related]
4. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Anderson DE; Kew KM; Boyter AC Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD011397. PubMed ID: 26301488 [TBL] [Abstract][Full Text] [Related]
5. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Kew KM; Evans DJ; Allison DE; Boyter AC Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392 [TBL] [Abstract][Full Text] [Related]
6. New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma. Thomson NC Expert Opin Pharmacother; 2017 Feb; 18(3):283-293. PubMed ID: 28099820 [TBL] [Abstract][Full Text] [Related]
7. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Chung KF; Caramori G; Adcock IM Eur J Clin Pharmacol; 2009 Sep; 65(9):853-71. PubMed ID: 19557399 [TBL] [Abstract][Full Text] [Related]
8. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
9. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Long-Acting Beta Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405 [TBL] [Abstract][Full Text] [Related]
11. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. Suissa S; Dell'Aniello S; Ernst P Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966 [TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroids with combination inhaled long-acting beta Tan DJ; White CJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584 [TBL] [Abstract][Full Text] [Related]
14. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242 [TBL] [Abstract][Full Text] [Related]
15. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Kew KM; Dias S; Cates CJ Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923 [TBL] [Abstract][Full Text] [Related]
16. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Oba Y; Keeney E; Ghatehorde N; Dias S Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694 [TBL] [Abstract][Full Text] [Related]
17. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis. Oba Y; Chandran AV; Devasahayam JV COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815 [TBL] [Abstract][Full Text] [Related]
18. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
20. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. Sobieraj DM; Baker WL; Nguyen E; Weeda ER; Coleman CI; White CM; Lazarus SC; Blake KV; Lang JE JAMA; 2018 Apr; 319(14):1473-1484. PubMed ID: 29554174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]